These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 16967055)

  • 1. Health state utilities for metastatic breast cancer.
    Lloyd A; Nafees B; Narewska J; Dewilde S; Watkins J
    Br J Cancer; 2006 Sep; 95(6):683-90. PubMed ID: 16967055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health state utilities for non small cell lung cancer.
    Nafees B; Stafford M; Gavriel S; Bhalla S; Watkins J
    Health Qual Life Outcomes; 2008 Oct; 6():84. PubMed ID: 18939982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health state utility scores in advanced non-small cell lung cancer.
    Doyle S; Lloyd A; Walker M
    Lung Cancer; 2008 Dec; 62(3):374-80. PubMed ID: 18467000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of health state utilities in neuroendocrine tumours.
    Swinburn P; Wang J; Chandiwana D; Mansoor W; Lloyd A
    J Med Econ; 2012; 15(4):681-7. PubMed ID: 22364284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elicitation of health state utilities in metastatic renal cell carcinoma.
    Swinburn P; Lloyd A; Nathan P; Choueiri TK; Cella D; Neary MP
    Curr Med Res Opin; 2010 May; 26(5):1091-6. PubMed ID: 20225993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health state utilities for metastatic breast cancer in Taiwan.
    Chou TC; Chiang SC; Ko Y
    Breast; 2020 Jun; 51():57-64. PubMed ID: 32213442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health state utilities in non-small cell lung cancer: An international study.
    Nafees B; Lloyd AJ; Dewilde S; Rajan N; Lorenzo M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e195-e203. PubMed ID: 26990789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study.
    Beusterien KM; Davies J; Leach M; Meiklejohn D; Grinspan JL; O'Toole A; Bramham-Jones S
    Health Qual Life Outcomes; 2010 May; 8():50. PubMed ID: 20482804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.
    Havrilesky LJ; Broadwater G; Davis DM; Nolte KC; Barnett JC; Myers ER; Kulasingam S
    Gynecol Oncol; 2009 May; 113(2):216-20. PubMed ID: 19217148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preference weights for chemotherapy side effects from the perspective of women with breast cancer.
    Kuchuk I; Bouganim N; Beusterien K; Grinspan J; Vandermeer L; Gertler S; Dent SF; Song X; Segal R; Mazzarello S; Crawley F; Dranitsaris G; Clemons M
    Breast Cancer Res Treat; 2013 Nov; 142(1):101-7. PubMed ID: 24129976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan.
    Takumoto Y; Sasahara Y; Narimatsu H; Murata T; Akazawa M
    Health Econ Rev; 2022 Dec; 12(1):63. PubMed ID: 36564539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.
    Tolley K; Goad C; Yi Y; Maroudas P; Haiderali A; Thompson G
    Eur J Health Econ; 2013 Oct; 14(5):749-59. PubMed ID: 22941034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.
    Walker MS; Hasan M; Yim YM; Yu E; Stepanski EJ; Schwartzberg LS
    Health Qual Life Outcomes; 2011 Jun; 9():46. PubMed ID: 21689425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health utility values associated with diabetic retinopathy.
    Lloyd A; Nafees B; Gavriel S; Rousculp MD; Boye KS; Ahmad A
    Diabet Med; 2008 May; 25(5):618-24. PubMed ID: 18346157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elicitation of health state utilities in soft tissue sarcoma.
    Shingler SL; Swinburn P; Lloyd A; Diaz J; Isbell R; Manson S; Benson C
    Qual Life Res; 2013 Sep; 22(7):1697-706. PubMed ID: 23100200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
    Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J
    Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliciting health state utilities from the general public for severe chronic pain.
    Eldabe S; Lloyd A; Verdian L; Meguro M; Maclaine G; Dewilde S
    Eur J Health Econ; 2010 Jun; 11(3):323-30. PubMed ID: 19680700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility values for specific hepatic encephalopathy health states elicited from the general public in the United Kingdom.
    Guest JF; Nanuwa K; Barden R
    Health Qual Life Outcomes; 2014 Jun; 12():89. PubMed ID: 24917331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health State Utility Assessment for Breast Cancer.
    Shih V; Chan A; Xie F; Ko Y
    Value Health Reg Issues; 2012 May; 1(1):93-97. PubMed ID: 29702834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.